US EditionPublished • loading... • Updated
Morepen Secures ₹825 Crore Global Deal, Expands Into High-Growth Cdmo Segment
Summary by India CSR Network
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Gurugram. Morepen Laboratories Limited (NSE: MOREPENLAB; BSE: 500288) has secured a multi-year Contract Development and Manufacturing Organization (CDMO) order from a leading global pharmaceutical company valued at approximately ₹825 crore (USD 91 million). Supplies under this order are expected to commence within the next 4–5 months, and will be executed by the first quarter (Q1) of the next financial year, subject to normal operational and reg…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
